Commentary: Digital health companies should stay away from FDA in 2021

As the agency’s workload swells with the weight of a public health emergency, digital health companies on a timeline should consider whether their products truly warrant a regulatory submission, writes Epstein Becker & Green’s Bradley Merrill Thompson.

Powered by WPeMatico